Investment Rating - The report maintains a "Buy" rating for the company, with expected net profits of 6.6 billion, 9.7 billion, and 13.6 billion RMB for the years 2025, 2026, and 2027 respectively, reflecting year-on-year growth of 15%, 46%, and 41% [5]. Core Insights - The company reported a revenue of 7.3 billion RMB for 2025, a year-on-year increase of 5.8%, and a net profit attributable to shareholders of 660 million RMB, up 14.9% year-on-year, indicating performance in line with expectations [2][4]. - Significant growth in the data center business and steady growth in the new energy and other business segments were highlighted, with the company transitioning from a single transformer supplier to a comprehensive power solution provider [3][4]. - The company is focusing on its core business and advancing digital transformation to optimize operational efficiency and management quality, which contributed to the increase in net profit [4]. Financial Summary - Revenue projections for the company are as follows: 6.668 billion RMB in 2023, 6.901 billion RMB in 2024, 7.299 billion RMB in 2025, 9.144 billion RMB in 2026, and 11.546 billion RMB in 2027, with respective growth rates of 40.5%, 3.5%, 5.8%, 25.3%, and 26.3% [9]. - The net profit attributable to shareholders is projected to be 505 million RMB in 2023, 574 million RMB in 2024, 660 million RMB in 2025, 967 million RMB in 2026, and 1.361 billion RMB in 2027, with growth rates of 78.15%, 13.82%, 14.93%, 46.46%, and 40.71% [9]. - The report indicates a diluted earnings per share of 1.182 RMB for 2023, increasing to 2.959 RMB by 2027 [9].

北交所信息更新 | 日期 | 2026/2/25 | | --- | --- | | 当前股价(元) | 16.92 | | 一年最高最低(元) | 38.00/16.22 | | 总市值(亿元) | 22.60 | | 流通市值(亿元) | 10.84 | | 总股本(亿股) | 1.34 | | 流通股本(亿股) | 0.64 | | 近 3 个月换手率(%) | 97.6 | 北交所研究团队 卡位汽车座椅智能化从零件到总成件，2025 年营收预计+28% ——北交所信息更新 诸海滨（分析师） zhuhaibin@kysec.cn 证书编号：S0790522080007 2025 年预计营收 3.90 亿元（+28.02%），归母净利润 8214.19 万元（+3.81%） 公司发布 2025 年业绩快报，预计 2025 年公司营业收入 3.90 亿元，同比增长 28.02%；归母净利润 8214.19 万元，同比增长 3.81%；我们维持 2025-2027 年盈 利预测，预计 2025-2027 年归母净利润分别为 0.81/1.02/1.26 亿元。EPS 分别为 0.61/0.76/0.95 元， ...

Investment Rating - The report maintains a "Buy" rating for the company, with expected net profits of 6.6 billion, 9.7 billion, and 13.6 billion for the years 2025, 2026, and 2027 respectively, reflecting year-on-year growth rates of 15%, 46%, and 41% [5]. Core Insights - The company reported a revenue of 7.3 billion in 2025, a year-on-year increase of 5.8%, and a net profit attributable to shareholders of 660 million, up 14.9% year-on-year, with Q4 revenue remaining stable at 2.11 billion [2][4]. - The data center business has shown significant growth, with the company transitioning from a single transformer supplier to a comprehensive power solution provider, which includes oil transformers, switchgear, and power modules, capitalizing on the increasing demand for computing power driven by the global AI and renewable energy trends [3][4]. - The company is focusing on its core business and advancing digital transformation to optimize operational efficiency and management quality, which has contributed to a net profit increase of 14.9% in 2025 [4]. Financial Summary - The company’s projected revenue growth rates are 40.5% for 2023, 3.5% for 2024, 5.78% for 2025, 25.27% for 2026, and 26.27% for 2027 [9]. - The net profit attributable to shareholders is expected to grow from 505 million in 2023 to 1.36 billion in 2027, with growth rates of 78.15%, 13.82%, 14.93%, 46.46%, and 40.71% respectively [9]. - The diluted earnings per share are projected to increase from 1.182 in 2023 to 2.959 in 2027 [9].

配用电全球化布局，持续突破海外市场 三星医疗(601567) | [姓名table_Authors] | 电话 | 邮箱 | 登记编号 | | --- | --- | --- | --- | | 徐强(分析师) | 010-83939805 | xuqiang@gtht.com | S0880517040002 | | 房青(分析师) | 021-23185603 | fangqing@gtht.com | S0880525040112 | 本报告导读： 公司智能配用电业务拥有全球化营销及运营体系，海外配电重点突破欧洲、中东、 拉美优势市场，国内配用电业务保持行业领先。 投资要点： | | | [Table_Invest] 首次覆盖 评级 增持 目标价格 32.40 | | | [Table_Market] 交易数据 | 52 周内股价区间(元) | 21.21-30.20 | | --- | --- | | 总市值(百万元) | 36,535 | | 总股本/流通A股(百万股) | 1,405/1,405 | | 流通 B股/H 股(百万股) | 0/0 | [Table_Balance] 资产负债表摘要( ...

"产品加服务",打造平安新的价值增长 中国平安(601318) ——中国平安更新报告 | [Table_Authors] 姓名 | 电话 | 邮箱 | 登记编号 | [Table_Invest] 评级： | 增持 | | --- | --- | --- | --- | --- | --- | | 刘欣琦(分析师) | 021-38676647 | liuxinqi@gtht.com | S0880515050001 | | | | 李嘉木(分析师) | 021-38038619 | lijiamu@gtht.com | S0880524030003 | [Table_Target] 目标价格(元): | 88.53 | 本报告导读： 中国平安战略定位 "综合金融"+"医疗养老"，依据三大竞争优势打造的"产品 +服务"模式将带来盈利长期的稳定增长，构成中国平安新的价值增长极。 投资要点： 催化剂：推动商业健康险的制度性政策 风险提示：资本市场波动；利率曲线持续下移。 | [Table_Finance] 财务摘要（百万元） | 2023A | 2024A | 2025E | 2026E | 2027E | | - ...

前沿生物-U(688221.SH)事件点评 与 GSK 达成 2 个小核酸合作，有望谱写全球发展新篇章 glmszqdatemark 此次与跨国药企 GSK 的合作也是公司全球发展战略的重要契机。一方面彰显了前 沿生物在早期 siRNA 药物发现与开发领域的专业能力，正获得国际市场认可；另 一方面，首付款及后续里程碑付款，可以改善公司现金流，助力公司实现研发资 源的高效配置与战略聚焦。未来，前沿生物可以借助 GSK 在全球临床开发与商业 化方面的资源与经验，加速公司管线的国际化价值转化，并为后续推进产品商业 化、拓展全球合作奠定坚实基础。 [盈利预测与财务指标 Table_Forcast] | 项目/年度 | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | | 营业收入（百万元） | 129 | 159 | 220 | 285 | | 增长率（%） | 13.3 | 23.1 | 38.0 | 29.5 | | 归属母公司股东净利润（百万元） | -201 | -186 | -182 | -174 | | 增长率（%） | 38. ...

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [1]. Core Insights - The report addresses key aspects of the company's development history, industry analysis of its core products (bulldozers and excavators), and the company's competitive advantages in these areas [3]. - The company is positioned as a leading player in the bulldozer market, advancing towards smart, high-end, and global operations [3]. - The report highlights the stable industry structure and the potential benefits from increased capital expenditure in mining and accelerated infrastructure projects [3]. Summary by Sections Company Overview - The company has evolved from its inception, fulfilling the mission of domesticating high-power bulldozers in China, thus eliminating reliance on imports for bulldozers over 180 horsepower [12][13]. - The company has a stable shareholding structure, with significant stakes held by Shandong Heavy Industry Group and Weichai Power [20][24]. - The company has seen a steady increase in overseas revenue, with the proportion rising from 38.7% in 2022 to 55.7% in the first half of 2025 [34]. Bulldozer Market Analysis - The global bulldozer market is expected to grow from 33.6 billion yuan in 2020 to 53.9 billion yuan by 2024, driven by infrastructure development and mining activities [45]. - The report indicates that the market concentration is high, with the top five manufacturers expected to hold a 66% market share by 2024 [45]. - The domestic market is projected to recover in 2024, with the company maintaining a leading market share of 64.7% [48]. Competitive Advantages - The company is recognized as the leader in the domestic bulldozer market, having maintained a market share above 60% since 2010 [49]. - The report suggests that the company's bulldozers are likely to benefit from a structural supply-demand imbalance, leading to potential price increases [3][6]. - The company has a unique position in the excavator market, with a focus on internal and external demand recovery, supported by various factors such as policy stimulation and large-scale engineering projects [4][6]. Financial Projections - Revenue is projected to grow from 14.22 billion yuan in 2024 to 20.16 billion yuan by 2027, with a compound annual growth rate (CAGR) of approximately 19% from 2020 to 2024 [5]. - The net profit attributable to shareholders is expected to increase from 1.10 billion yuan in 2024 to 1.93 billion yuan in 2027, reflecting a strong growth trajectory [5]. - The report anticipates a stable gross margin and improved profitability due to effective cost control measures [29].

证券研究报告 | 公司深度报告 2026 年 02 月 25 日 大族激光（002008.SZ） 苹果创新加速+算力 PCB 扩产，激光龙头迎接新一轮高成长 TMT 及中小盘/电子 招商电子团队深度跟踪过大族历史上五轮向上期，我们判断公司正进入新一轮 AI 端侧与算力共振的向上周期：1）AI 端侧：苹果 26-27 年 AI 硬件加速创新， 公司消费电子业务不仅受益于散热/光学等创新，更重要是望在 3D 打印赛道成 为领导者；2）算力：PCB 机械钻孔设备需求旺盛且盈利提升明显，超快钻孔 实现 0-1 突破打开新成长空间；3）其他业务：新能源/半导体/通用等总体稳中 向好，商业航天等新兴行业拓展下游应用领域。考虑到公司再迎新一轮向上周 期，业绩有超预期潜力，且估值向上弹性大，维持"强烈推荐"投资评级。 强烈推荐（维持） 当前股价：63.38 元 基础数据 | 总股本（百万股） | 1030 | | --- | --- | | 已上市流通股（百万股） | 957 | | 总市值（十亿元） | 65.3 | | 流通市值（十亿元） | 60.6 | | 每股净资产（MRQ） | 16.5 | | ROE（TTM） ...

前沿生物-U(688221.SH)事件点评 与 GSK 达成 2 个小核酸合作，有望谱写全球发展新篇章 glmszqdatemark 此次与跨国药企 GSK 的合作也是公司全球发展战略的重要契机。一方面彰显了前 沿生物在早期 siRNA 药物发现与开发领域的专业能力，正获得国际市场认可；另 一方面，首付款及后续里程碑付款，可以改善公司现金流，助力公司实现研发资 源的高效配置与战略聚焦。未来，前沿生物可以借助 GSK 在全球临床开发与商业 化方面的资源与经验，加速公司管线的国际化价值转化，并为后续推进产品商业 化、拓展全球合作奠定坚实基础。 [盈利预测与财务指标 Table_Forcast] | 项目/年度 | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | | 营业收入（百万元） | 129 | 159 | 220 | 285 | | 增长率（%） | 13.3 | 23.1 | 38.0 | 29.5 | | 归属母公司股东净利润（百万元） | -201 | -186 | -182 | -174 | | 增长率（%） | 38. ...

投资要点： "产品加服务",打造平安新的价值增长 中国平安(601318) ——中国平安更新报告 | [Table_Authors] 姓名 | 电话 | 邮箱 | 登记编号 | [Table_Invest] 评级： | 增持 | | --- | --- | --- | --- | --- | --- | | 刘欣琦(分析师) | 021-38676647 | liuxinqi@gtht.com | S0880515050001 | | | | 李嘉木(分析师) | 021-38038619 | lijiamu@gtht.com | S0880524030003 | [Table_Target] 目标价格(元): | 88.53 | 本报告导读： 中国平安战略定位 "综合金融"+"医疗养老"，依据三大竞争优势打造的"产品 +服务"模式将带来盈利长期的稳定增长，构成中国平安新的价值增长极。 催化剂：推动商业健康险的制度性政策 风险提示：资本市场波动；利率曲线持续下移。 | [Table_Finance] 财务摘要（百万元） | 2023A | 2024A | 2025E | 2026E | 2027E | | - ...